Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC)
| Autor: | David R. Spigel, R. C. Inhorn, J. R. Infante, E. Vazquez, John D. Hainsworth, Charles D. Webb, H. A. Burris, J. R. Rubinsak, D. A. Yardley, F. A. Greco |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty integumentary system biology Cetuximab business.industry Standard treatment non-small cell lung cancer (NSCLC) medicine.disease digestive system diseases Gemcitabine Docetaxel Internal medicine biology.protein Effective treatment Medicine Epidermal growth factor receptor Receptor business neoplasms medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 26:19045-19045 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2008.26.15_suppl.19045 |
| Popis: | 19045 Background: Disrupting epidermal growth factor receptor signaling is an effective treatment strategy in NSCLC. Cetuximab targets this receptor and is a standard treatment in colon and head an... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|